American Journal of Cardiology
Volume 102, Issue 6 , Pages 743-748 , 15 September 2008

Prognosis and Risk Factors in Patients With Asymptomatic Aortic Stenosis and Their Modulation by Atorvastatin (20 mg)

  • Wolfgang Dichtl, MD, PhD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • Corresponding Author InformationCorresponding author: Tel: 43-512-504-81307; fax: 43-512-504-22767
    • ,
  • Hannes Franz Alber, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Gudrun Maria Feuchtner, MD

      Affiliations

    • Clinical Department of Radiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Florian Hintringer, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Markus Reinthaler, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Thomas Bartel, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Alois Süssenbacher, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Wilhelm Grander, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Hanno Ulmer, PhD

      Affiliations

    • Department of Medical Statistics, Informatics and Health Economics, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Otmar Pachinger, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Silvana Müller, MD

      Affiliations

    • Clinical Department of Cardiology, Medical University Innsbruck, Innsbruck, Austria

Received 2 March 2008 ,Revised 26 April 2008 ,Accepted 26 April 2008.

References 

  1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732
  2. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–147
  3. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic valvular aortic stenosis (Clinical, echocardiographic and exercise predictors of outcome). Circulation. 1997;95:2262–2270
  4. Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M, Gabriel H, et al. Mild and moderate aortic stenosis (Natural history and risk stratification by echocardiography). Eur Heart J. 2004;25:199–205
  5. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–617
  6. Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg. 2006;82:2116–2122
  7. Galante A, Pietroiusti A, Vellini M, Piccolo P, Possati G, De Bonis M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol. 2001;38:1078–1082
  8. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004;109:2302–2308
  9. Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, et al. Clinical factors, but not C-reactive protein, predict progression of calcified aortic-valve disease (The Cardiovascular Health Study). J Am Coll Cardiol. 2007;50:1992–1999
  10. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–2397
  11. Mohler ER, Wang H, Medenilla E, Scott C. Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis. 2007;16:378–386
  12. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–695
  13. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205–2209
  14. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol level, HMG-CoA reductase inhibitor treatment and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723–1730
  15. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291–1295
  16. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554–561

PII: S0002-9149(08)00846-1

doi: 10.1016/j.amjcard.2008.04.060

American Journal of Cardiology
Volume 102, Issue 6 , Pages 743-748 , 15 September 2008

Article Tools

* Image Usage & Resolution